“Around 40% of all the investigated ADCs are targeting cancers of B and T–Cell known as Lymphomas”, says RNCOS.
Noida, UP -- (SBWIRE) -- 12/23/2014 -- According to a new research report by RNCOS entitled, "Global Antibody Drug Conjugate Market Outlook 2018", around 40% of ADCs under development has been aiming to treat lymphomas. Lymphomas are tumors belonging to the lymphocytes such as B and T cell lymphocytes. There are two main types: Hodgkin Lymphoma and Non Hodgkin Lymphoma, Non Hodgkin Lymphoma makes up about 90% of cases.
Supported by this fact, most ADCs under-development is targeting NHL, and few of them are progressing in late clinical trials. For e.g., ADC developed by Seattle Genetics for NHL is in second phase of clinical development. Also Immunomedics has been focusing on ADC to target NHL, which is about to enter in phase II. Apart from NHL, ADCs are targeting Hodgkin Lymphoma also. Other targets for ADC have been breast cancers, Leukemia, Renal carcinoma and gastric cancers.
This report is spread over 60 pages and provides an in-depth research and rational analysis of the current status and future prospect of the Antibody Drug Conjugate market. The report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved.
The report also provides an insight into the key ADCs that are currently in pipeline. A brief analysis on the types of ADCs is being done on the basis of types of drug used, clinical phases and cancers targeted. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided.
At the end, major players of ADC market have been discussed. A brief business overview of every player has been provided alongwith their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM667.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.